GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Asset Turnover

Nova Mentis Life Science (Nova Mentis Life Science) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Nova Mentis Life Science's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Nova Mentis Life Science's Total Assets for the quarter that ended in Mar. 2024 was $0.04 Mil. Therefore, Nova Mentis Life Science's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Nova Mentis Life Science's annualized ROE % for the quarter that ended in Mar. 2024 was 73.74%. It is also linked to ROA % through Du Pont Formula. Nova Mentis Life Science's annualized ROA % for the quarter that ended in Mar. 2024 was -1,211.43%.


Nova Mentis Life Science Asset Turnover Historical Data

The historical data trend for Nova Mentis Life Science's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Asset Turnover Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.20 -

Competitive Comparison of Nova Mentis Life Science's Asset Turnover

For the Biotechnology subindustry, Nova Mentis Life Science's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's Asset Turnover falls into.



Nova Mentis Life Science Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Nova Mentis Life Science's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (0.688+0.219)/ 2 )
=0/0.4535
=0.00

Nova Mentis Life Science's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (0.04+0.03)/ 2 )
=0/0.035
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Nova Mentis Life Science  (OTCPK:NMLSF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Nova Mentis Life Science's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-0.424/-0.575
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.424 / 0)*(0 / 0.035)*(0.035/ -0.575)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.0609
=ROA %*Equity Multiplier
=-1,211.43 %*-0.0609
=73.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Nova Mentis Life Science's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-0.424/0.035
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.424 / 0)*(0 / 0.035)
=Net Margin %*Asset Turnover
= %*0
=-1,211.43 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Nova Mentis Life Science Asset Turnover Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

By PRNewswire PRNewswire 11-09-2021

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022